YHB Investment Advisors Inc. Acquired New Positions in Shares of Charles River Laboratories International, Inc. (NYSE: CRL – Get Rating) in the Third Quarter, According to Latest Filings with the U.S. Securities and Exchange Commission (SEC) Did. An institutional investor acquired 1,035 shares of a medical research company worth approximately $204,000.
→ Trade with confidence in 2023! (From Tradewinds)
Other big investors have also recently changed their stakes in the company. Vestmark Advisory Solutions Inc. increased his stake in Charles River Laboratories International by 8.2% in the third quarter. Vestmark Advisory Solutions Inc. now owns 36,170 shares of the medical research company worth $7,118,000 after purchasing an additional 2,734 of his shares during this period. Manufacturers’ Life Insurance Company increased Charles River’s Laboratories International holding by 310.3% in the third quarter. After purchasing an additional 166,507 shares during this period, Manufacturers Life Insurance Company now owns 220,174 shares of the medical research company worth $43,228,000. Trustcore Financial Services LLC increased its stake in Charles River Laboratories International by 72.0% in the third quarter. Trustcore Financial Services LLC now owns 172 shares of the medical research company worth $34,000 after purchasing an additional 72 shares during this period. Hunter Associates Investment Management LLC increased its stake in Charles River Laboratories International by 5.4% in the third quarter. Hunter Associates Investment Management LLC now owns 1,415 shares of the medical research company valued at $274,000 after purchasing an additional 72 shares during this period. Finally, Daiwa Securities Group Inc. increased its holding of Charles River Laboratories International by 5.5% in the third quarter. Daiwa Securities Group now owns 3,407 shares of the medical research company worth $670,000 after purchasing an additional 178 shares during this period. Currently 97.80% of the shares are owned by institutional investors and hedge funds.
Analyst Rating Change
Many research analysts have their eyes on the CRL stock. JPMorgan Chase & Co. lowered its price target on Charles River Laboratories International stock from $280.00 to $275.00 in its research notes on Thursday, November 3, giving the stock an “overweight” rating. bottom. StockNews.com began covering the stock of Charles River Laboratories International in a research report on Wednesday, October 12th. They put a “Hold” rating on the stock. Jefferies Financial Group downgraded shares of Charles River Laboratories International from a ‘buy’ to a ‘hold’ rating in a research report on Thursday, January 12. Morgan Stanley lowered its stock price target for Charles His River His Laboratories His International from his $250.00 to his $241.00, setting an “equal-weighted” rating on the stock in a research report on Thursday, Nov. 3. Did. Finally, Credit Suisse Group lowered its price target for Charles River Laboratories International from $285.00 to $280.00 in its research report on Thursday, November 3, giving the stock an “outperform” rating. bottom. Four equity research analysts rated the stock with a hold rating and 11 gave the company a buy rating. According to MarketBeat, the company has an average rating of “moderate buy” and an average target price of $297.38.
Charles River Laboratories International Trading increased by 4.1%
CRL shares opened at $243.17 on Friday. The company has a market capitalization of $12.37 billion, a price/earnings ratio of 28.64, a PEG ratio of 1.53 and a beta of 1.29. The company has a debt to equity ratio of 1.12, a quick ratio of 1.14 and a current ratio of 1.40. Charles River Laboratories International, Inc. has a 52-week low of $181.36 and a 52-week high of $349.84. The company has a 50-day moving average price of $226.53 and a 200-day moving average price of $218.49.
Charles River Laboratories International (NYSE:CRL – Get Rating) last reported quarterly results on Wednesday, November 2nd. The medical research firm reported EPS of $2.63 for the quarter, beating analysts’ consensus forecast of $2.51 by $0.12. Charles River Laboratories International had a net profit margin of 11.54% and a return on equity of 20.93%. The company’s revenue for the quarter was $989.16 million, compared with analyst estimates of $978.65 million. As a group, equity research analysts expect Charles River Laboratories International, Inc. to post his 10.89 earnings per share this year.
Insider trading at Charles River Laboratories International
In related news, EVP Shannon M. Parisotto sold 2,279 shares in a transaction that took place on Tuesday, November 15th. The shares sold for an average of $249.90, giving him a total of $569,522.10. Following the closing of the sale, the Executive Vice President now directly owns 2,499 shares of the Company’s stock valued at approximately $624,500.10. The transaction is disclosed in legal documents to the Securities and Exchange Commission, available at this hyperlink. In separate news, EVP Joseph W. Laplume said he sold 534 shares of Charles River Laboratories International in a deal on Friday, November 4th. The shares sold at an average price of $216.36, and the total transaction value he had was $115,536.24. Following the closing of the sale, Executive His Vice President now owns directly his 20,232 shares valued at $4,377,395.52. The transaction was disclosed in SEC filings that can be accessed through the SEC’s website. EVP Shannon M. Parisotto also sold 2,279 shares of Charles River Laboratories International in a transaction on Tuesday, November 15th. The shares were sold at an average price of $249.90 for a total of $569,522.10. Following the sale, the Executive Vice President now owns 2,499 shares of the Company stock valued at $624,500.10. Please see here for the disclosure of this sale. In the past 90 days, the insider has sold 10,077 shares of his company stock worth $2,334,821. A company insider owns his 1.10% of the company’s shares.
About Charles River Laboratories International
(get rating)
Charles River Laboratories International, Inc is a nonclinical contract research organization providing drug discovery, nonclinical development and safety testing services in the United States, Europe, Canada, Asia Pacific and internationally. He operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Related item
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.
Listen to this before considering Charles River Laboratories International.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to their clients to buy now before the broader market catches on…and Charles River Laboratories International is on the list. There was not.
Charles River Laboratories International currently holds a ‘Medium Buy’ rating among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here
